Learn More
Individual cases of prolonged complete response (CR) of HER2-positive metastatic breast cancer (MBC) have been reported following treatment with trastuzumab/chemotherapy, but the frequency of durable remission is unknown [1, 2]. We carried out a retrospective study of long-term outcome of all patients with HER2-positive MBC treated in our institutions with(More)
Fulvestrant for advanced male breast cancer patients: a case series Male breast cancer is rare and treatment recommendations are mainly extrapolated from the results of trials on women. Most breast cancers in men are estrogen receptor (ER)/ progesterone receptor (PgR) positive; as a consequence, tamoxifen remains the standard adjuvant treatment and is also(More)
We report the case of a 34-year-old woman affected by breast cancer that had metastasized to the bone. She had been treated with oral cyclophosphamide and methotrexate (metronomic chemotherapy) and achieved 3.5 years of clinical remission. To our knowledge, this is the first description of such a prolonged response to therapy. This case report adds weight(More)
BACKGROUND Breast cancer micrometastases are frequently found during pathological examination of sentinel lymph nodes and complete axillary lymph node dissection. Despite this, their clinical relevance is still debated. The aim of this study is to investigate features that affect disease-free survival (DFS) and overall survival (OS) in patients with nodal(More)
  • 1